Prescriber, operator, purchaser, payer and patient — separate incentives in potassium monitoring during RAASi titration

1. Summary

Five parties touch potassium and creatinine monitoring during RAASi titration — prescriber, operator, purchaser, payer and patient — and this pass could locate published, quantified evidence for only two of them. Nurse- or pharmacist-led titration programs outperform physician-only titration at getting patients onto guideline-directed RAAS-inhibitor doses, a finding that holds across a 16-trial randomized meta-analysis and an independent single-site US program, which is why the party who actually interprets a potassium result and decides whether to hold or resume titration is frequently not the physician whose name is on the prescription. Federal regulation confirms the mechanism by which a payer's incentive to see a specific test performed can exist at all: CMS folds externally developed, private-sector quality measures into the Medicare Advantage Star Ratings system that sets plan bonus payments, rather than writing every measure itself. What prescribers report as their own barriers to titrating heart-failure medication is documented in two qualitative studies; what the purchaser weighs in equipping a clinic for point-of-care testing, and what the patient experiences of the monitoring burden itself, are not — this pass located no source for either.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

Prescriber — the party titrating the drug, and what already makes them stop

Two evidence types back this row: what prescribers report as their own barriers, and what they are recorded doing once a lab value comes back abnormal. In-depth interviews with 31 clinicians (58% primary care, 42% cardiology; 26% from federally qualified health centers) across a US integrated health system and FQHCs found "clinical inertia," time constraints and patient frailty as recurring barriers to intensifying heart-failure quadruple therapy, and in the FQHC setting specifically, "limited access to and communication with cardiology specialists" as an added constraint [1] [single-source]. A separate scoping review of 23 qualitative studies of physician perspectives on heart-failure prescribing (not US-limited) found "concern for medication adverse effects" was the most commonly identified barrier across studies, alongside "unclear role responsibilities between physicians of different specialities" [2] [single-source]. Hyperkalemia is exactly the adverse effect this domain's monitoring exists to catch, and what prescribers do once it appears is measurable rather than hypothetical: in a 905-patient outpatient RAASi cohort (Jeddah, Saudi Arabia, mean follow-up 29.8 months), hyperkalemia (K+ ≥5.1 mmol/L) occurred in 32.8% and led to discontinuation in 6.2% and down-titration in a further 4.5% [5] [single-source]. In the US CHAMP-HF registry (heart failure with reduced ejection fraction, median follow-up 18 months), 12.7% of ACEi/ARB users, 10.4% of ARNI users and 20.4% of MRA users discontinued therapy over follow-up, and greater investigator clinical experience independently predicted a lower risk of discontinuing ACEi/ARB and MRA therapy specifically — a prescriber-level, not only a patient-level, predictor [6] [single-source].

Operator — the party who runs the titration workflow, and it is often not the prescriber of record

A pooled analysis of 16 randomized trials (5,268 patients; 82% testing a nurse intervention, the remainder pharmacist) found that assigning guideline-directed therapy initiation and up-titration to a nurse or pharmacist rather than the physician alone nearly doubled the rate of renin-angiotensin-system-inhibitor initiation (risk ratio 2.09, 95% CI 1.05–4.16) and up-titration (risk ratio 1.99, 95% CI 1.24–3.20) [3]. A single-site US pharmacist-run "heart failure medication titration clinic," seeing 80 of 974 screened HFrEF patients, produced a statistically significant increase in triple- and quadruple-therapy attainment at 90 days [4] [single-source]. Read together, these are two independent, non-affiliated sources agreeing on the same direction of effect, so the underlying claim — that a nurse- or pharmacist-operator model outperforms physician-only titration — is stated plainly above; the specific effect sizes attached to each study remain single-source. The practical consequence for this domain: the party who would actually order, run or interpret a point-of-care potassium test in a titration workflow is frequently practicing under a collaborative or delegated authority, not the physician of record, which is a distinct incentive structure — workload, delegated scope of practice, program funding — from the prescriber's.

Purchaser — no source located

No source located this pass reports the capital or per-test cost a clinic or health system would weigh in deciding whether to add point-of-care potassium/creatinine testing capacity, or the staffing time such testing would add to a nurse- or pharmacist-led titration visit. This row carries no citable finding.

Payer — a documented mechanism, not a documented dollar amount

Federal regulation confirms the mechanism by which a health-plan-level quality measure can become a financial incentive rather than only a clinical recommendation. The regulation governing how CMS adds a measure to the Medicare Advantage and Part D Star Ratings states that CMS "will continue to review measures that are nationally endorsed and in alignment with the private sector, such as measures developed by National Committee for Quality Assurance (NCQA) and the Pharmacy Quality Alliance (PQA), or endorsed by the National Quality Forum for adoption and use in the Part C and Part D Quality Ratings System" [7]. Star Ratings determine a Medicare Advantage plan's quality bonus payment, which is the step that converts an externally-developed measure into a plan-level incentive; this pass retrieved only the measure-adoption provision itself, not a document tying a named medication-monitoring measure to a bonus-payment calculation, so the connection is stated here as a mechanism, not as a number.

Patient — no source located

No published source located this pass reports patients' own experience of the venous-draw cycle, or any patient-level driver of adherence to RAASi therapy attributable to the burden of laboratory monitoring specifically, as distinct from the clinician-recorded reaction to an abnormal result already covered under Prescriber above. This row carries no citable finding; see Section 5 for what was searched.

4. Sources

[1] Barriers and Facilitators to Heart Failure Guideline-Directed Medical Therapy in an Integrated Health System and Federally Qualified Health Centers: A Thematic Qualitative Analysis — Journal of General Internal Medicine (published 2026, month not given in the PubMed record; accessed 2026-09-01). PMID 40325339 — https://pubmed.ncbi.nlm.nih.gov/40325339/ [peer-reviewed] [2] Physician Perceptions of Medication Prescribing in Heart Failure: A Scoping Review — Cardiology (published 2025, month not given in the PubMed record; accessed 2026-09-01). PMID 38801813 — https://pubmed.ncbi.nlm.nih.gov/38801813/ [peer-reviewed] [3] Pharmacist- and Nurse-Led Medical Optimization in Heart Failure: A Systematic Review and Meta-Analysis — Journal of Cardiac Failure (published 2023-07; accessed 2026-09-01). PMID 37004867 — https://pubmed.ncbi.nlm.nih.gov/37004867/ [peer-reviewed] [4] Impact of Pharmacist-Led Heart Failure Clinic on Optimization of Guideline-Directed Medical Therapy (PHARM-HF) — Journal of Cardiovascular Translational Research (published 2022-12; accessed 2026-09-01). PMID 35501544 — https://pubmed.ncbi.nlm.nih.gov/35501544/ [peer-reviewed] [5] Real-world insights into hyperkalemia burden and RAASi discontinuation: a cohort study — Current Medical Research and Opinion (published 2025, month not given in the PubMed record; accessed 2026-09-01). PMID 41126484 — https://pubmed.ncbi.nlm.nih.gov/41126484/ [peer-reviewed] [6] Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction — Journal of Cardiac Failure (published 2022, month not given in the PubMed record; accessed 2026-09-01). PMID 34428591 — https://pubmed.ncbi.nlm.nih.gov/34428591/ [peer-reviewed] [7] Section 422.164, Adding, updating, and removing measures — eCFR, retrieved via this repo's regulation connector (issue 2026-08-13; accessed 2026-09-01). 42 CFR 422.164 — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-422/subpart-D/section-422.164 [federal-registry]

5. Sourcing & Gaps

Well established: that a nurse- or pharmacist-operator model outperforms physician-only titration at achieving guideline-directed RAAS-inhibitor doses rests on two independent, non-affiliated sources — a 16-trial randomized meta-analysis [3] and an independent single-site US program [4] — and is stated plainly for that reason.

Thin: every specific figure attached to the prescriber and operator rows rests on a single study and carries [single-source] — the interview-study barrier list [1], the scoping-review barrier ranking [2], the 90-day GDMT-attainment result [4], the Jeddah discontinuation rates [5], and the CHAMP-HF discontinuation rates and experience effect [6]. The payer row's regulatory mechanism [7] is a single registry text and is stated plainly per this fleet's convention for class-1 registry facts, not because it has been independently corroborated by a second document.

Rescoped from class 3: "would prescribers, pharmacists or patients adopt a new potassium monitoring device" is not answerable and was not asked directly. Its revealed-behaviour twins are what each already does: prescribers already discontinue or down-titrate RAASi at a measured rate once a lab potassium is high [5][6] — evidence that the underlying clinical problem is live, not evidence that any new device would be adopted; and nurse- or pharmacist-led programs already produce a measurably different titration outcome than physician-only care [3][4] — evidence that operator identity changes outcomes, not evidence that any specific device or workflow change would be accepted by that operator. Whether a payer would specifically reimburse or reward a device that automates this monitoring is a different, unanswered question from the regulatory mechanism found in [7], which concerns an existing lab-test-based measure, not any device.

Out of scope: CPT descriptors, which are AMA-licensed and are not reproduced anywhere in this repo; fda.gov guidance documents, which gate automated requests intermittently; any jurisdiction beyond the US.

Not searched vs. not found:

• Not found: a specific NCQA/HEDIS quality-measure specification naming potassium and creatinine monitoring for ACE-inhibitor, ARB and diuretic users was independently confirmed this pass via a directly-fetched health-plan provider-education document (a Medicaid managed-care plan's own "Guidelines for HEDIS Effectiveness of Care Measures" handout, identifying the measure as "Annual Monitoring for Patients on Persistent Medications"), but that document carries no PMID, NCT, K-number, CFR section, HCPCS code, DOI, CELEX number or FR Doc number — nothing this report's closed identifier vocabulary can resolve — so it is disclosed here rather than written as a numbered citation in Section 3; only the underlying CFR mechanism that lets such measures affect payment [7] is carried as a citable finding. No primary NCQA/HEDIS specification document itself was fetched (the specification is subscription content).
• Not found: purchaser-side capital, per-test cost, or staffing-time data for point-of-care potassium/creatinine testing in this care setting; a study reporting patients' own experience of laboratory-monitoring burden, needle aversion, or a monitoring-attributable adherence driver distinct from a clinician's reaction to an abnormal result. One qualitative study of 16 heart-failure patients and 16 caregivers was read at abstract depth and found to report self-care barriers ("limited capability," "insufficient external support," "lack of motivation") with no mention of laboratory monitoring specifically, and is therefore not carried forward as evidence for the patient row.
• Not searched: state-by-state variation in pharmacist collaborative-practice-agreement scope for ordering or acting on lab values; payer coverage of pharmacist- or nurse-led titration visits themselves (distinct from the lab test); caregiver incentives, which this pass treated as outside the five-party frame given in the task rather than as a sixth row.

[inference] That the operator-effect finding in [3] and [4] implies a device aimed at this domain should be designed around a pharmacist/nurse workflow rather than a physician-facing one is this writer's synthesis. Neither source discusses any monitoring device; both describe a prescribing- and visit-scheduling model.

6. Claim Candidates